Edwards Lifesciences Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated May 2, 2026, discloses the appointment of a new Chief Financial Officer (CFO) for Edwards Lifesciences Corporation. The report details the terms of employment and compensation for the incoming executive, effective May 29, 2026.
Key Financial Metrics
The filing does not contain operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The financial data provided relates exclusively to the compensation package for the new CFO:
- Base Salary: $925,000 annually.
- Target Annual Bonus: 100% of base salary ($925,000).
- Sign-on Bonus: $2,013,000 (subject to pro-rata repayment if employment ends within 24 months).
- Initial Equity Grant (RSUs): $8,000,000 grant date value.
- Annual Equity Award (FY 2026): $4,500,000 grant date value.
Material Changes
The primary material change is the leadership transition in the finance function. Theodora Mistras is appointed to succeed Scott B. Ullem as Corporate Vice President and CFO. Ms. Mistras joins from Viatris, Inc., where she served as CFO since March 2024, following a 15-year tenure in healthcare investment banking at Goldman Sachs and Citigroup.
Outlook, Risks, and Unusual Items
Employment Terms: The appointment is an at-will relationship with no specified term. The RSU vesting schedule is 43.75% on the first anniversary, 50% on the second, and 6.25% on the third anniversary of the start date.
Severance and Change-in-Control: Ms. Mistras is eligible for a Change-in-Control (CIC) agreement. In the event of termination without Cause or resignation for Good Reason, the initial RSU award vests in full. Non-change-in-control severance includes one year of base salary plus one year of target bonus, a pro-rated bonus, and $50,000 in outplacement benefits.
Other Benefits: The company will reimburse up to $15,000 in legal fees and cover relocation costs from New York to Orange County, California.
Investor Verification Checklist
- Verify the effective start date of May 29, 2026, and the departure timeline for the outgoing CFO, Scott B. Ullem.
- Review the attached Offer Letter (Exhibit 10.1) for specific definitions of "Cause" and "Good Reason" regarding equity acceleration and severance.
- Confirm the impact of the $2,013,000 sign-on bonus and $8,000,000 initial RSU grant on the company's immediate and future stock-based compensation expense.
- Assess the strategic implications of hiring a CFO with a background in investment banking and pharmaceuticals (Viatris) for a medical device company.